Limits...
Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models.

Tamura T - Asia Pac Allergy (2012)

Bottom Line: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions.These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

View Article: PubMed Central - PubMed

Affiliation: Marketing Department Sales & Marketing Division and Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Tokyo 100-8185, Japan.

ABSTRACT

Background: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP release by anti-allergic ophthalmic solutions.

Objective: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.

Methods: Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models.

Results: Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva.

Conclusion: These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

No MeSH data available.


Related in: MedlinePlus

Effects of olopatadine ophthalmic solution and other anti-allergic ophthalmic solutions on substance P (SP) contents in tears induced by ovalbumin in passively sensitized rats. SP contents were measured 30 min after antigen challenge. Ophthalmic solutions were instilled at 30 min before antigen challenge and immediately after antigen challenge into the bilateral eye at 10 µL/site. Each column and vertical bar represents the mean ± SE of 5-7 rats. *p < 0.05, **p < 0.01, ***p < 0.001: significantly different from the control group (Student's t-test). †p < 0.05: significantly different from the olopatadine 0.1% group (Student's t-test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3345324&req=5

Figure 4: Effects of olopatadine ophthalmic solution and other anti-allergic ophthalmic solutions on substance P (SP) contents in tears induced by ovalbumin in passively sensitized rats. SP contents were measured 30 min after antigen challenge. Ophthalmic solutions were instilled at 30 min before antigen challenge and immediately after antigen challenge into the bilateral eye at 10 µL/site. Each column and vertical bar represents the mean ± SE of 5-7 rats. *p < 0.05, **p < 0.01, ***p < 0.001: significantly different from the control group (Student's t-test). †p < 0.05: significantly different from the olopatadine 0.1% group (Student's t-test).

Mentions: To elucidate the SP release of olopatadine and other anti-allergic ophthalmic solutions, we determined the levels of SP in tears using rat antigen-induced conjunctivitis model (Fig. 4). The levels of SP in tears were significantly increased by the OVA challenge compared with normal rats. Olopatadine 0.1% and 0.2% significantly inhibited the increase in the levels of SP in tears (p = 0.0054, p = 0.0005). The levels of SP in tears after application of olopatadine 0.2% was significantly less than those of application of olopatadine 0.1% (p = 0.0225). Tranilast also significantly inhibited the increase in the levels of SP (p = 0.0392). On the other hand, levocabastine did not inhibit the increase in the levels of SP.


Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models.

Tamura T - Asia Pac Allergy (2012)

Effects of olopatadine ophthalmic solution and other anti-allergic ophthalmic solutions on substance P (SP) contents in tears induced by ovalbumin in passively sensitized rats. SP contents were measured 30 min after antigen challenge. Ophthalmic solutions were instilled at 30 min before antigen challenge and immediately after antigen challenge into the bilateral eye at 10 µL/site. Each column and vertical bar represents the mean ± SE of 5-7 rats. *p < 0.05, **p < 0.01, ***p < 0.001: significantly different from the control group (Student's t-test). †p < 0.05: significantly different from the olopatadine 0.1% group (Student's t-test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3345324&req=5

Figure 4: Effects of olopatadine ophthalmic solution and other anti-allergic ophthalmic solutions on substance P (SP) contents in tears induced by ovalbumin in passively sensitized rats. SP contents were measured 30 min after antigen challenge. Ophthalmic solutions were instilled at 30 min before antigen challenge and immediately after antigen challenge into the bilateral eye at 10 µL/site. Each column and vertical bar represents the mean ± SE of 5-7 rats. *p < 0.05, **p < 0.01, ***p < 0.001: significantly different from the control group (Student's t-test). †p < 0.05: significantly different from the olopatadine 0.1% group (Student's t-test).
Mentions: To elucidate the SP release of olopatadine and other anti-allergic ophthalmic solutions, we determined the levels of SP in tears using rat antigen-induced conjunctivitis model (Fig. 4). The levels of SP in tears were significantly increased by the OVA challenge compared with normal rats. Olopatadine 0.1% and 0.2% significantly inhibited the increase in the levels of SP in tears (p = 0.0054, p = 0.0005). The levels of SP in tears after application of olopatadine 0.2% was significantly less than those of application of olopatadine 0.1% (p = 0.0225). Tranilast also significantly inhibited the increase in the levels of SP (p = 0.0392). On the other hand, levocabastine did not inhibit the increase in the levels of SP.

Bottom Line: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions.These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

View Article: PubMed Central - PubMed

Affiliation: Marketing Department Sales & Marketing Division and Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Tokyo 100-8185, Japan.

ABSTRACT

Background: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP release by anti-allergic ophthalmic solutions.

Objective: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.

Methods: Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models.

Results: Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva.

Conclusion: These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

No MeSH data available.


Related in: MedlinePlus